Protecting Children Against Omicron
Open Access
- 14 June 2022
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 327 (22), 2195-2197
- https://doi.org/10.1001/jama.2022.7315
Abstract
Prior to emergence of the Omicron SARS-CoV-2 variant, and at the time of the issuance of the Emergency Use Authorization (EUA) for the BNT162b2 (Pfizer-BioNTechThis publication has 16 references indexed in Scilit:
- Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccinePublished by Research Square Platform LLC ,2022
- Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022Morbidity and Mortality Weekly Report (MMWR), 2022
- Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational studyBMJ, 2022
- Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US AdolescentsJAMA Network Open, 2022
- Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2Published by Cold Spring Harbor Laboratory ,2022
- Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous InfectionThe New England Journal of Medicine, 2022
- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta VariantsJAMA, 2022
- Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in AdolescentsThe New England Journal of Medicine, 2021
- Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of AgeThe New England Journal of Medicine, 2021
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsThe New England Journal of Medicine, 2021